Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Hookipa Pharma Inc. (HOOK) since 2019 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Hookipa Pharma Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1760542.
Total stock buying since 2019: $18,288,422.
Total stock sales since 2019: $7,471,426.
Total stock option exercises since 2019: $15,330.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 42,785 | $39,361 | 0 | $0 |
| 2023 | 47,000 | $38,442 | 0 | $0 | 0 | $0 |
| 2021 | 0 | $0 | 414,949 | $5,692,190 | 22,853 | $2,285 |
| 2020 | 0 | $0 | 126,722 | $1,546,185 | 78,271 | $7,825 |
| 2019 | 1,303,570 | $18,249,980 | 21,888 | $193,690 | 52,203 | $5,220 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-07 | 0 | $0 | 42,785 | $39,361 | 0 | $0 |
| 2023-08 | 15,000 | $10,787 | 0 | $0 | 0 | $0 |
| 2023-07 | 20,000 | $17,095 | 0 | $0 | 0 | $0 |
| 2023-06 | 12,000 | $10,560 | 0 | $0 | 0 | $0 |
| 2021-12 | 0 | $0 | 14,949 | $37,223 | 22,853 | $2,285 |
| 2021-03 | 0 | $0 | 400,000 | $5,654,967 | 0 | $0 |
| 2020-12 | 0 | $0 | 28,359 | $332,639 | 49,628 | $4,962 |
| 2020-10 | 0 | $0 | 300 | $3,000 | 0 | $0 |
| 2020-09 | 0 | $0 | 41,597 | $532,732 | 0 | $0 |
| 2020-07 | 0 | $0 | 12,483 | $149,096 | 0 | $0 |
| 2020-06 | 0 | $0 | 9,840 | $115,884 | 0 | $0 |
| 2020-01 | 0 | $0 | 34,143 | $412,834 | 28,643 | $2,863 |
| 2019-12 | 0 | $0 | 21,888 | $193,690 | 52,203 | $5,220 |
| 2019-04 | 1,303,570 | $18,249,980 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-22 | Peters Malte (Chief Executive Officer) | Sale | 29,176 | .92 | 26,841 |
| 2025-07-22 | Coelho Mary Theresa (EVP and CFO) | Sale | 13,609 | .92 | 12,520 |
| 2023-08-21 | Kandera Reinhard (Chief Financial Officer) | Buy | 7,000 | .72 | 5,075 |
| 2023-08-16 | Kandera Reinhard (Chief Financial Officer) | Buy | 8,000 | .71 | 5,712 |
| 2023-07-11 | Aldag Jorn (Chief Executive Officer) | Buy | 5,000 | .83 | 4,140 |
| 2023-07-07 | Aldag Jorn (Chief Executive Officer) | Buy | 5,000 | .81 | 4,050 |
| 2023-07-05 | Aldag Jorn (Chief Executive Officer) | Buy | 5,000 | .89 | 4,450 |
| 2023-07-03 | Aldag Jorn (Chief Executive Officer) | Buy | 5,000 | .89 | 4,455 |
| 2023-06-30 | Kandera Reinhard (Chief Financial Officer) | Buy | 12,000 | .88 | 10,560 |
| 2021-12-21 | Matushansky Igor (Chief Medical Officer) | Sale | 14,949 | 2.49 | 37,223 |
| 2021-12-21 | Matushansky Igor (Chief Medical Officer) | Option Ex | 22,853 | .10 | 2,285 |
| 2021-03-29 | Sofinnova Partners Sas | Sale | 36,829 | 13.67 | 503,562 |
| 2021-03-26 | Sofinnova Partners Sas | Sale | 35,171 | 13.69 | 481,631 |
| 2021-03-25 | Sofinnova Partners Sas | Sale | 28,546 | 13.12 | 374,580 |
| 2021-03-24 | Sofinnova Partners Sas | Sale | 52,690 | 13.70 | 721,642 |
| 2021-03-23 | Sofinnova Partners Sas | Sale | 40,000 | 13.91 | 556,480 |
| 2021-03-22 | Sofinnova Partners Sas | Sale | 40,534 | 14.54 | 589,283 |
| 2021-03-19 | Sofinnova Partners Sas | Sale | 166,230 | 14.61 | 2,427,789 |
| 2020-12-17 | Matushansky Igor (Chief Medical Officer) | Sale | 27,979 | 11.73 | 328,193 |
| 2020-12-17 | Matushansky Igor (Chief Medical Officer) | Option Ex | 48,988 | .10 | 4,898 |
| 2020-12-16 | Matushansky Igor (Chief Medical Officer) | Sale | 380 | 11.70 | 4,446 |
| 2020-12-16 | Matushansky Igor (Chief Medical Officer) | Option Ex | 640 | .10 | 64 |
| 2020-10-02 | Sofinnova Partners Sas (10% Owner) | Sale | 300 | 10.00 | 3,000 |
| 2020-09-15 | Sofinnova Partners Sas (10% Owner) | Sale | 41,597 | 12.81 | 532,732 |
| 2020-07-20 | Sofinnova Partners Sas (10% Owner) | Sale | 12,483 | 11.94 | 149,096 |
| 2020-06-29 | Sofinnova Partners Sas (10% Owner) | Sale | 6,560 | 11.78 | 77,256 |
| 2020-01-29 | Matushansky Igor (Chief Medical Officer) | Sale | 5,500 | 12.73 | 69,993 |
| 2020-01-23 | Lilja Anders (Sr. VP, Technical Development) | Sale | 11,643 | 12.49 | 145,421 |
| 2020-01-23 | Lilja Anders (Sr. VP, Technical Development) | Option Ex | 11,643 | .10 | 1,164 |
| 2020-01-21 | Orlinger Klaus (Sr. VP, Research) | Sale | 6,789 | 12.02 | 81,590 |
| 2020-01-21 | Orlinger Klaus (Sr. VP, Research) | Option Ex | 6,789 | .10 | 678 |
| 2020-01-16 | Orlinger Klaus (Sr. VP, Research) | Sale | 1,711 | 11.56 | 19,780 |
| 2020-01-16 | Orlinger Klaus (Sr. VP, Research) | Option Ex | 1,711 | .10 | 171 |
| 2020-01-14 | Orlinger Klaus (Sr. VP, Research) | Sale | 8,500 | 11.30 | 96,050 |
| 2020-01-14 | Orlinger Klaus (Sr. VP, Research) | Option Ex | 8,500 | .10 | 850 |
| 2019-12-19 | Matushansky Igor (Chief Medical Officer) | Sale | 10,404 | 9.93 | 103,311 |
| 2019-12-19 | Matushansky Igor (Chief Medical Officer) | Option Ex | 25,891 | .10 | 2,589 |
| 2019-12-17 | Matushansky Igor (Chief Medical Officer) | Sale | 11,484 | 7.87 | 90,379 |
| 2019-12-17 | Matushansky Igor (Chief Medical Officer) | Option Ex | 26,312 | .10 | 2,631 |
| 2019-04-23 | Forbion Capital Fund Ii Cooperatief U.a. (10% Owner) | Buy | 53,571 | 14.00 | 749,994 |
| 2019-04-23 | Sofinnova Partners Sas (10% Owner) | Buy | 357,142 | 14.00 | 4,999,988 |
| 2019-04-23 | Baker Julian (Other) | Buy | 892,857 | 14.00 | 12,499,998 |
Insider trading activities including stock purchases, stock sales, and option exercises of HOOK listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Hookipa Pharma Inc. (symbol HOOK, CIK number 1760542) see the Securities and Exchange Commission (SEC) website.